gemcitabine + carboplatin + cisplatin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non Small Cell Lung
Conditions
Carcinoma, Non Small Cell Lung
Trial Timeline
Sep 1, 2001 → Jul 1, 2006
NCT ID
NCT00191230About gemcitabine + carboplatin + cisplatin
gemcitabine + carboplatin + cisplatin is a phase 2 stage product being developed by Eli Lilly for Carcinoma, Non Small Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00191230. Target conditions include Carcinoma, Non Small Cell Lung.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191230 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Non Small Cell Lung